Chronic High-Dose Buprenorphine Does Not Block Subjective High from Diacetylmorphine in a Patient in Heroin-Assisted Treatment

References

• Beltrutti, D., and D. Niv. 2000. Pain relief after simultaneous administration of intravenous buprenorphine and intrathecal morphine in terminally ill patients; A report of two cases. The Pain Clinic 12 (2):121–23. doi:10.1163/156856900750229889.
   Web of Science ®Google Scholar
• Beltrutti, D., D. Niv, R. Ben-Abraham, S. Di Santo, and A. A. Weinbroum. 2002. Late antinociception and lower untoward effects of concomitant intrathecal morphine and intravenous buprenorphine in humans. Journal of Clinical Anesthesia 14 (6):441–46. doi:10.1016/S0952-8180(02)00397-5.
   PubMed Web of Science ®Google Scholar
• Brown, S. M., M. Holtzman, T. Kim, and E. D. Kharasch. 2011. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, Are biologically active. Anesthesiology 115 (6):1. doi:10.1097/ALN.0b013e318238fea0.
   PubMed Web of Science ®Google Scholar
• Brust, T. F., J. Morgenweck, S. A. Kim, J. H. Rose, J. L. Locke, C. L. Schmid, L. Zhou, E. L. Stahl, M. D. Cameron, S. M. Scarry, et al. 2016. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Science Signaling 9 (456):ra117–ra117. doi:10.1126/scisignal.aai8441.
   PubMed Web of Science ®Google Scholar
• Comer, S. D., E. A. Walker, and E. D. Collins. 2005. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 181 (4):664–75. doi:10.1007/s00213-005-0023-6.
   PubMed Web of Science ®Google Scholar
• Crow, R., H. Gage, S. Hampson, J. Hart, A. Kimber, and H. Thomas. 1999. The role of expectancies in the placebo effect and their use in the delivery of health care: A systematic review. Health Technology Assessment (Winchester, England) 3 (3):1–96.
   PubMedGoogle Scholar
• Elkader, A., and B. Sproule. 2005. Buprenorphine: Clinical pharmacokinetics in the treatment of opioid dependence. Clinical Pharmacokinetics 44 (7):661–80. doi:10.2165/00003088-200544070-00001.
   PubMed Web of Science ®Google Scholar
• Gear, R. W., C. Miaskowski, N. C. Gordon, S. M. Paul, P. H. Heller, and J. D. Levine. 1996. Kappa-opioids produce significantly greater analgesia in women than in men. Nature Medicine 2 (11):1248–50. doi:10.1038/nm1196-1248.
   PubMed Web of Science ®Google Scholar
• Gorelick, D. A., Y. K. Kim, B. Bencherif, S. J. Boyd, R. Nelson, M. Copersino, C. J. Endres, R. F. Dannals, and J. J. Frost. 2005. Imaging brain Mu-opioid receptors in abstinent cocaine users: Time course and relation to cocaine craving. Biological Psychiatry 57 (12). Elsevier:1573–82. doi:10.1016/J.BIOPSYCH.2005.02.026.
   PubMed Web of Science ®Google Scholar
• Gossop, M. 1990. The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors 15 (5):487–90. doi:10.1016/0306-4603(90)90036-W.
   PubMed Web of Science ®Google Scholar
• Greenwald, M. K., C.-E. Johanson, D. E. Moody, J. H. Woods, M. R. Kilbourn, R. A. Koeppe, C. R. Schuster, and J.-K. Zubieta. 2003. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology 28 (11):2000–09. doi:10.1038/sj.npp.1300251.
   PubMed Web of Science ®Google Scholar
• Greenwald, M. K., K. J. Schuh, J. A. Hopper, C. R. Schuster, and C.-E. Johanson. 2002. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology 160 (4):344–52. doi:10.1007/s00213-001-0975-0.
   PubMed Web of Science ®Google Scholar
• Greenwald, M. K., S. D. Comer, and D. A. Fiellin. 2014. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy. Drug and Alcohol Dependence 144:1–11. doi:10.1016/j.drugalcdep.2014.07.035.
   PubMed Web of Science ®Google Scholar
• Hämmig, R., A. Kemter, J. Strasser, U. von Bardeleben, B. Gugger, M. Walter, K. M. Dürsteler, and M. Vogel. 2016. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: The Bernese method. Substance Abuse and Rehabilitation 7:99–105. doi:10.2147/SAR.S109919.
   PubMed Web of Science ®Google Scholar
• Indivior Inc. 2018. Subutex [package insert]. North Chesterfield, VA: Indivior Inc.
   Google Scholar
• Jasinski, D. R., and K. L. Preston. 1995. Laboratory studies of buprenorphine in opioid abusers. In Buprenorphine. Combatting drug abuse with a unique opioid, ed. A. Cowan and J. Lewis, 189–211. New Yotk, NY: Wiley-Liss, Inc.
   Google Scholar
• Levin, F. R., M. W. Fischman, I. Connerney, and R. W. Foltin. 1997. A protocol to switch high-dose, methadone-maintained subjects to buprenorphine. American Journal on Addictions 6 (2):105–16. doi:10.3109/10550499709137021.
   PubMed Web of Science ®Google Scholar
• Mattick, R. P., C. Breen, J. Kimber, and M. Davoli. 2014. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Edited by Richard P Mattick. Cochrane Database of Systematic Reviews 2 (2). Chichester, UK: John Wiley & Sons, Ltd:CD002207. doi:10.1002/14651858.CD002207.pub4.
   Google Scholar
• Mello, N. K., and J. H. Mendelson. 1980. Buprenorphine suppresses heroin use by heroin addicts. Science (New York, N.Y.) 207 (4431):657–59. doi:10.1126/science.207.4435.1030.
   PubMed Web of Science ®Google Scholar
• Schwienteck, K. L., S. S. Negus, and M. L. Banks. 2018. Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys. Behavioural Pharmacology 1. doi:10.1097/FBP.0000000000000437.
   PubMed Web of Science ®Google Scholar
• Unger, A., E. Jung, B. Winklbaur, and G. Fischer. 2010. Gender issues in the pharmacotherapy of opioid-addicted women: Buprenorphine. Journal of Addictive Diseases 29 (2). NIH Public Access:217–30. doi:10.1080/10550881003684814.
   PubMed Web of Science ®Google Scholar
• van Niel, J., J. Schneider, and T. Tzschentke. 2016. Efficacy of full µ-opioid receptor agonists is not impaired by concomitant buprenorphine or mixed opioid agonists/antagonists – preclinical and clinical evidence. Drug Research © Georg Thieme Verlag KG. doi:10.1055/s-0042-109393.
   Web of Science ®Google Scholar
• Walsh, S. L., H. L. June, K. J. Schuh, K. L. Preston, G. E. Bigelow, and M. L. Stitzer. 1995. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 119 (3):268–76. doi:10.1007/BF02246290.
   PubMed Web of Science ®Google Scholar
• Welsh, C., S. G. Sherman, and K. E. Tobin. 2008. A case of heroin overdose reversed by sublingually administered buprenorphine/naloxone (Suboxone). Addiction (Abingdon, England) 103 (7):1226–28. doi:10.1111/j.1360-0443.2008.02244.x.
   PubMed Web of Science ®Google Scholar
• Zhang, L., J. Wang, J. Chen, Y. Tao, Y. Wang, X. Xu, J. Chen, Y. Xu, T. Xi, X. Hu, et al. 2015. Novel κ-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation. Acta Pharmacologica Sinica 36(5). Nature Publishing Group:565–71. doi:10.1038/aps.2014.145.
   PubMed Web of Science ®Google Scholar
• Zubieta, J. K., D. A. Gorelick, R. Stauffer, H. T. Ravert, R. F. Dannals, and J. J. Frost. 1996. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nature Medicine 2 (11):1225–29. doi:10.1038/nm1196-1225.
   PubMed Web of Science ®Google Scholar
• Zubieta, J. K., R. F. Dannals, and J. J. Frost. 1999. Gender and age influences on human brain mu-opioid receptor binding measured by PET. The American Journal of Psychiatry 156 (6):842–48. doi:10.1176/ajp.156.6.842.
   PubMed Web of Science ®Google Scholar